Divi's Laboratories — India's second largest pharmaceutical company by market value — on Monday reported an 18.6 percent fall in net profit to Rs 493.6 crore for the July-September period compared with the corresponding quarter a year ago, falling short of Street estimates. Its revenue fell 6.7 percent on year to Rs 1,854.5 crore for the three-month period.
The Divi's stock slumped as much as 7.7 percent to Rs 3,458.3 apiece on BSE after the earnings announcement.
Analysts in a CNBC-TV18 poll had estimated the drug maker's quarterly net profit at Rs 579.3 crore and revenue at Rs 2,201 crore.
Its earnings before interest, taxes, depreciation and ammortisation (EBITDA) declined 24.1 percent to Rs 621 crore for the quarter ended September 2022.
The margin of Hyderabad-based Divi's Labs contracted by 760 basis points on year to 33.5 percent. The analysts had pegged the company's margin at 38.1 percent. Margin is the degree to which a business generates money.
The drug maker reported a forex gain of Rs 30 crore for the three-month period, as against a forex loss of Rs 7 crore for the year-ago period.
Divi's Laboratories shares have shed more than seven percent of their value in the past one month, a period in which the Nifty50 benchmark has risen five percent.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Phase five Lok Sabha polls: Rae Bareli, Amethi among 14 UP seats going to polls on Monday
May 19, 2024 1:03 PM
AAP protest walk: Arvind Kejriwal challenges BJP to arrest entire party, Delhi Police imposes Section 144
May 19, 2024 12:26 PM
Terror attacks in Kashmir raise concerns ahead of May 20 and May 25 election
May 19, 2024 12:15 PM